UPDATE 1-Novartis breast cancer drug Kisqali wins European panel backing
June 23, 2017 at 05:55 AM EDT
ZURICH, June 23 (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.
